Mr. Yuk Lam Lo
Independent Director
Sinovac
Sinovac Biotech
China
Biography
Mr. Yuk Lam Lo has served as an independent director of Sinovac since March 2006. Mr. Lo is the chair of the Corporate Governance and Nominating Committee and a member of the Audit and Compensation Committees. Mr. Lo has been heavily involved in several committees of the HKSAR Government. He was appointed director of the Hong Kong Applied R&D Fund Co. Ltd., chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund. Currently Mr. Lo is serving as a member of the Advisory Council for Food Safety for the Food and Health Bureau, a director of the Chinese Manufacturers’ Association of Hong Kong (CMA) and chairman of the Innovation and Technology Committee of CMA. Mr. Lo is also the honorary founding chairman of Hong Kong Bio-Organization. Additionally, Mr. Lo has been elected an honorary fellow of the Hong Kong University of Science and Technology. He is a member of the Advisory Committee of the Vocational Training Council, an executive vice-president of the Asian College of Management, adjunct professor of the Chinese University of Hong Kong and honorary professor of several universities in China. In China, Mr. Lo was a consultant to the Economic Bureau of Changchun and a member of the Advisory Committee of the Shenzhen Municipal Science and Technology Bureau. At present, he is a consultant for the Centre for Disease Control and Prevention of China. Mr. Lo has almost 30 years of experience as Asia Pacific regional president for two multi-national technology companies, Bio-Rad (NYSE:BIO) and Perkin Elmer (NYSE:PKI), and is currently now the chairman of Lo’s Associates Ltd., vice-chairman of Santai Eco-Fishery Ltd., vice-chairman of APlus OTC Health Group Ltd., senior advisor to Questmark Capital Management Sdn. Bhd., and Senior Director of Questmark Asia Ltd. Mr. Lo is also an independent director of South East Group Ltd. (0726.HK) and Shangpharma (NYSE:SHP).
Research Interest
Molecular Biology and Molecular Genetics